Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI
May 2, 2024 4:48 PM EDTEvercore ISI analyst Vijay Kumar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $14.50 (from $15.00) while maintaining a In Line rating.
The analyst comments "NVCR reported headline revs of $139 MM, up +13% y/y (vs -11% comp) with total revs coming in slightly above ST. Total revs incl ~$4.2 MM from prior period claims in U.S., ex which magnitude of the Beat was ~3%. Active patients and TRx both grew... More
